Summary: Isolated distal deep-vein thrombosis (DDVT) of the lower extremities can be associated with subsequent proximal deep-vein thrombosis (PDVT) and/or acute pulmonary embolism (PE). We aimed to develop a model predicting the probability of developing PDVT and/or PE within three months after an isolated episode of DDVT. We conducted a retrospective cohort study of patients with symptomatic DDVT confirmed by lower extremity vein ultrasounds between 2001–2012 in the Cleveland Clinic Health System. We reviewed all the ultrasounds, chest ventilation/perfusion and computed tomography scans ordered within three months after the initial DDVT to determine the incidence of PDVT and/or PE. A multiple logistic regression model was built to predict the rate of developing these complications. The final model included 450 patients with isolated DDVT. Within three months, 30 (7%) patients developed an episode of PDVT and/or PE. Only two factors predicted subsequent thromboembolic complications: inpatient status (OR, 6.38; 95 % CI, 2.17 to 18.78) and age (OR, 1.02 per year; 95 % CI, 0.99 to 1.05). The final model had a bootstrap bias-corrected c-statistic of 0.72 with a 95 % CI (0.64 to 0.79). Outpatients were at low risk ( 10%). Inpatients aged < 60 were at intermediate risk. We created a simple model that can be used to risk stratify patients with isolated DDVT based on inpatient status and age. The model might be used to choose between anticoagulation and monitoring with serial ultrasounds.
The current COVID-19 crisis has significantly impacted healthcare systems worldwide. There has been a palpable increase in public avoidance of hospitals, which has interfered in timely care of critical cardiovascular conditions. Complications from late presentation of myocardial infarction, which had become a rarity, resurfaced during the pandemic. We present two such encounters that occurred due to delay in seeking medical care following myocardial infarction due to the fear of contracting COVID-19 in the hospital. Moreover, a comprehensive review of literature is performed to illustrate the potential factors delaying and decreasing timely presentations and interventions for time-dependent medical emergencies like ST-segment elevation myocardial infarction (STEMI). We emphasise that clinicians should remain vigilant of encountering rare and catastrophic complications of STEMI during this current era of COVID-19 pandemic.
18 November 2025 in Journal of the American Heart Association
Background: Current anticancer treatments can result in cancer therapy–related cardiac dysfunction (CTRCD). While glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have demonstrated cardioprotective properties, their role in CTRCD has not been previously explored. Methods: This retrospective cohort study utilized the TriNetX research network. Adults aged ≥18 years who had a cancer history and who underwent antineoplastic therapy and developed CTRCD between January 1, 2012 and January 1, 2023 were included. Among patients on guideline‐directed medical therapy for heart failure, 2 groups were identified: GLP‐1 RA users and nonusers. Propensity score matching (1:1) was conducted based on demographics, comorbid conditions, and concurrent medications, yielding a matched sample of 837 patients. Outcomes were assessed over a 1‐year follow‐up period. Results: The study cohort found 4982 patients with CTRCD; 837 received GLP‐1 RA therapy (mean age: 69.0 years; 43.8% female; 70.4% White). Compared with nonusers, those treated with GLP‐1 RAs alongside guideline‐directed medical therapy had significantly lower rates of all‐cause mortality (hazard ratio, 0.57 [95% CI, 0.43–0.77]; P <0.001), acute heart failure exacerbations (hazard ratio, 0.69 [95% CI, 0.56–0.85]; P <0.001), and all‐cause hospitalizations (hazard ratio, 0.83 [95% CI, 0.72–0.96]; P =0.009). While reductions in atrial fibrillation/flutter and ventricular tachycardia were observed, they were not statistically significant. Conclusion: Among patients with CTRCD receiving guideline‐directed medical therapy, GLP‐1 RA use may be linked to better 1‐year survival and improved heart failure–related outcomes.
17 May 2021 in American Journal of Health-System Pharmacy
Studies have supported the use of packaging interventions such as pillboxes or blister packs to improve medication adherence but have not evaluated the efficacy of these interventions in a population of low socioeconomic status. The aim of this study was to assess the effect of home-delivered pill packs on medication adherence in a low-income Black American population with Medicaid insurance. This study was an open-label, randomized, controlled trial. The patient population studied included 80 patients followed by primary care physicians at the Cleveland Clinic. Patients were randomized to a study group who received delivery of their multidrug medical therapy, defined as a minimum of 4 medications daily, in prepackaged blisters or a control group who obtained their prescriptions from their routine pharmacy. The primary analysis compared the mean percentage of missed pills between the 2 groups using t-test analysis. The percentage of missed pills in the study group was significantly lower than in the control group (mean [SD]: 3.7% [6.0%] vs 17.4% [16.6%] missed daily pills; P < 0.001). The number of daily missed doses was also significantly lower in the study group (0.3 [0.5] vs 0.7 [0.6]; P = 0.002). Patients were on a mean of 8.1 (SD, 2.3) and 8.1 (SD, 2.6) medications in the study and control groups, respectively (P = 0.96). Delivery of prepackaged medications in a low-income Black American community was demonstrated to improve medication adherence. The use of prepackaged blisters for medication home delivery is a model that can be utilized on a larger scale for patients on multidrug medical therapy.
The first case of coronavirus disease 2019 (COVID-19) in the USA was reported on 19 January 2020. Over the ensuing months, the virus spread throughout the country and a national emergency was declared on 13 March 2020. There was a significant burden on healthcare services related to the pandemic, with a parallel decline in patients seeking healthcare services for non-coronavirus-related illnesses. There was also uncertainty among healthcare systems to provide non-coronavirus-related care while keeping patients and healthcare providers safe. These circumstances beckoned a rapid transformation of healthcare delivery to provide ongoing care while ensuring safety of both patients and providers. It became pivotal to embrace technological advances, which vastly depended on virtual platforms.